/
DVA
$222.72+$3.02 (+1.37%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$13.9B
64M shares
52-week range
$101.00 – $222.85
100% from low
Sector
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
Exchange
NYSE
CS
Borrow rate
0.29%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$100.39
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.40B | $11.39B | $11.55B | $11.62B | $11.61B | $12.14B | $12.82B | $13.64B |
| Cost of revenue | $8.20B | $7.91B | $7.99B | $7.97B | $8.21B | $8.32B | $8.60B | $9.96B |
| Gross profit | $3.21B | $3.47B | $3.56B | $3.65B | $3.40B | $3.82B | $4.22B | $3.68B |
| Gross margin | 28.1% | 30.5% | 30.8% | 31.4% | 29.3% | 31.5% | 32.9% | 27.0% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $1.53B | $1.64B | $1.69B | $1.80B | $1.34B | $1.60B | $2.09B | $2.01B |
| EBITDA | $2.13B | $2.25B | $2.25B | $2.48B | $2.06B | $2.32B | $2.72B | $2.64B |
| Net income | $159.4M | $811.0M | $773.6M | $978.5M | $560.4M | $691.5M | $936.3M | $746.8M |
| Net margin | 1.4% | 7.1% | 6.7% | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
| EPS (diluted) | 4.58 | 5.27 | 6.39 | 8.90 | 5.71 | 7.42 | 10.73 | 9.51 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14.1B | $14.85 | $14.29–$15.79 | 4 |
| 2027 | $14.5B | $17.28 | $16.10–$18.43 | 4 |
| 2028 | $14.6B | $18.95 | $18.54–$19.64 | 1 |
| 2029 | $15.9B | $18.12 | $17.72–$18.77 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$230.10
Price
$222.72
Implied upside
+3%
Peer comparison
DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
www.davita.com- Employees
- 78,000
- IPO / List date
- Oct 31, 1995
- HQ
- DENVER, CO
Held by traders on TradeandTell
No one on the platform currently holds DVA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Berkshire Hathawayas of 2026-03-31 | 33,796,541 | $4.8B |
| Renaissance Technologiesas of 2026-03-31 | 189,200 | $29.1M |
Stock splits
| Execution date | Ratio |
|---|---|
| 2013-09-09 | 2-for-1 |
| 2004-06-16 | 3-for-2 |
Recent trades on TradeandTell
No one on the platform has traded DVA yet.
